Policy & Regulation
Verona Pharma updates on clinical development
13 February 2018 -

Verona Pharma plc (LON: WRP) has brought forward the timing for top-line data readouts for its ongoing clinical trials in chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) following clinical development updates, the company revealed on Tuesday.

The Phase 2b clinical trial of nebulised RPL554 for COPD maintenance treatment is now expected to report top-line data in the second quarter of 2018, brought forward from mid-2018.

The four-week, double-blind, placebo-controlled, parallel group Phase 2b study involved around 400 patients with moderate-to-severe COPD and took place at numerous sites across Europe. The aim of the study was to investigate the efficacy, safety and dose-response of nebulised RPL554.

Verona Pharma has also brought forward reporting of top-line data from the Phase 2a pharmacokinetic (PK) and pharmacodynamic (PD) clinical trial of RPL54 for CF to the late first quarter of 2018, from the first half of 2018.

The double-blind, placebo-controlled, cross-over Phase 2a study is evaluating the PK and PD profile and tolerability of a single nebulised dose of RPL554 and the effect on lung function in 10 patients with CF.